Table 1.
Characteristics of the patients according to the presence of AMR.
| Patient Characteristics | AMR Positive Group n = 25 |
AMR Negative Group n = 131 |
p |
|---|---|---|---|
| Mean summarized expression of ETA receptor score | 3.28 ± 1.56 | 1.47 ± 1.35 | <0.000001 |
| Recipient age (years) | 41.7 ± 15 | 43.4 ± 14 | NS |
| Male gender, n (%) | 16 (64%) | 88 (67.1%) | NS |
| No. of HLA ABDR mismatches | 3.75 ± 0.82 | 3.56 ± 1.1 | NS |
| A | 1.5 ± 0.5 | 1.32 ± 0.6 | NS |
| B | 1.25 ± 0.4 | 1.35 ± 0.6 | NS |
| DR | 0.9 ± 0.4 | 0.88 ± 0.6 | NS |
| No. (%) of presensitized patients | |||
| max PRA < 10% | 17 (68%) | 111 (84.7%) | 0.0001 |
| max PRA 10–50% | 7 (28%) | 13 (9.9%) | 0.01 |
| max PRA > 50% | 1 (4%) | 7 (5.3%) | NS |
| First/next transplantation | 24/1 | 121/10 | NS |
| Cold ischemia time (hours) | 22.4 ± 9.2 | 21.1 ± 9.8 | NS |
| Donor male gender (%) | 57% | 58% | NS |
| Donor age (years) | 43.7 ± 16.3 | 50.3 ± 13.2 | NS |
| Cause of chronic renal failure: | |||
| Chronic glomerulonephritis | 8 | 59 | NS |
| Diabetic nephropathy | 2 | 14 | NS |
| Hypertonic nephropathy | 3 | 17 | NS |
| Polycystic kidney disease | 3 | 12 | NS |
| Interstitial nephritis | 3 | 12 | NS |
| Other | 6 | 17 | NS |
| Initial immunosuppression | |||
| Tacrolimus | 16 (64%) | 92 (70.2%) | NS |
| Cyclosporin | 9 (36% | 39 (39.7%) | NS |
| MMF/MPA | 25 (100%) | 128 (97.7%) | NS |
| Azatioprine | 0 (0%) | 3 (2.3%) | NS |
| Steroids | 25 (100%) | 131 (100%) | NS |